ITACA: A New Validated International Erythropoietic Stimulating Agent-Response Score that Further Refines the Predictive Power of Previous Scoring Systems

R. Buckstein, E. Balleari, R. Wells, V. Santini, A. Sanna, C. Salvetti, E. Crisa, B. Allione, P. Danise, C. Finelli, M. Clavio, A. Poloni, F. Salvi, D. Cilloni, E. N. Oliva, P. Musto, B. Houston, N. Zhu, M. Geddes, H. LeitchB. Leber, M. Sabloff, T. J. Nevill, K. Yee, J. M. Storring, J. Francis, L. Maurillo, R. Latagliata, M. A. A. Spiriti, A. Andriani, A. L. Piccioni, L. Fianchi, S. Fenu, S. Gumenyuk, F. Buccisano

Research output: Contribution to journalArticlepeer-review


BACKGROUND: In 'real-life', the Nordic score guides ESA use in lower-risk MDS with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed. OBJECTIVES: To validate existing ESA predictive scores and develop a new score that identifies non-responders. METHODS: ESA-treated patients were identified in 3 MDS registries in Italy and Canada (FISM 555, GROM 233, MDS-CAN 208). Clinical and disease-related variables were captured. Nordic, MDS-CAN and IPSS-R-based ESA scores were calculated and documented ESA responses compared. RESULTS: 996 ESA-treated patients were identified. Overall response rate(ORR) was 59%. The database was randomly divided into balanced derivation (n=463) and validation (n=462) cohorts. By multivariate analysis, transfusion independence, erythropoietin level
Original languageEnglish
Pages (from-to)1037-1046
Number of pages10
JournalAmerican Journal of Hematology
Issue number10
Publication statusPublished - Oct 2017

Cite this